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Serotonin, a known neurotransmitter, also functions as an angiokine to promote angiogenesis. The
majority of serotonin in the human body is stored in platelets, and platelet aggregation leads to
signiﬁcant release of serotonin in thrombotic tumor environment. We have investigated serotonin
signaling in human endothelial cells. Through G-protein-coupled receptors, serotonin at physiolog-
ically relevant concentrations activated Src/PI3K/AKT/mTOR/p70S6K phosphorylation signaling, and
this activation was similar to that seen with VEGF. This ﬁnding provides insight into the overlapping
angiogenic signaling pathways stimulated by serotonin in tumor environment, and suggests one of
the mechanisms underlying resistance to current VEGF-targeting antiangiogenic therapy against
cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The monoamine neurotransmitter serotonin (5-hydroxytrypta-
mine (5-HT)) affects various neurological functions such as mood,
sleep, and appetite [1]. In addition to its functions in the human
central nervous system (CNS), 5-HT also plays important roles in
peripheral tissues. It regulates primary homeostasis, gut motility,
immune responses, and vasoconstriction. 5-HT also stimulates
endothelial cells to release vasodilating substances, and acts as a
‘‘helper agonist’’ of platelet aggregation [2]. The biosynthesis of
5-HT is carried out primarily by serotonergic neurons and entero-
chromafﬁn cells in the gastrointestinal tract. Enterochromafﬁn
cells produce and secrete approximately 90% of the total 5-HT in
the human body. Under normal conditions, 5-HT cannot cross the
blood–brain barrier [3]. Most peripheral 5-HT is incorporated into
platelets and circulates in the bloodstream throughout the entire
human vascular system [4].
Pro-thrombotic diseases such as cancer and atherosclerosis are
associated with high platelet counts and abnormalities of platelet
aggregation [5,6]. Endothelial cells are the main structural compo-
nents of blood vessels, and are one of the ﬁrst cell types that
encounter 5-HT upon its release from activated platelets. The stim-chemical Societies. Published by E
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ni), zhicanqu@gmail.com (Z.ulatory effects of 5-HT on the proliferation, migration, and tubulo-
genesis of endothelial cells [7–10] suggest that 5-HT plays a critical
role in angiogenesis. In recent years, several studies have approved
the concept that tumor growth is dependent upon angiogenesis
[11,12]. Vascular endothelial growth factor (VEGF) has been con-
sidered as a major tumor angiogenic factor [13]. Several agents tar-
geting VEGF or the VEGF receptor have been approved as
antiangiogenic therapy for cancer. Unfortunately, the beneﬁts of
these drugs are limited and transient, and are often followed by
resistance and the restoration of tumor progression [11,14]. These
ﬁndings suggest that other angiogenic factors may also drive tu-
mor angiogenesis. In the thrombotic environment of tumors, plate-
let aggregation frequently occurs and leads to signiﬁcant release of
serotonin, which may constitute one of the mechanisms of tumor
angiogenesis.2. Results
2.1. 5-HT activates signaling kinases in human endothelial cells
Several key signaling kinases have been shown to be involved in
angiogenic signal transduction in human endothelial cells [15–18].
5-HT has been demonstrated to have angiogenic potential. There-
fore, we assessed if 5-HT could activate certain angiogenic signal-
ing kinases. Seven signaling kinases were selected for the present
study; Src kinase; phosphatidylinositol 3-kinase (PI3K); protein ki-
nase B (AKT); mammalian target of rapamycin (mTOR); 70-kDa
ribosomal protein S6 kinase (p70S6K); p44/42 mitogen-activatedlsevier B.V. All rights reserved.
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(p38 MAPK). Four primary endothelial cell lines were used: human
umbilical vein endothelial cells (HUVECs), human microvascular
endothelial cells (HMVECs), human pulmonary artery endothelial
cells (HPAECs), and human aortic endothelial cells (HAECs). These
cells were examined for kinase activation upon 5-HT stimulation
with western blot analyses.
5-HT (1 lM) could activate all seven signaling kinases (Src,
PI3K, AKT, mTOR, p70S6K, ERK, and p38 MAPK; Fig. 1A). In healthy
human subjects, the mean level of 5-HT was approximately 10 pM
in plasma, 1 lM in serum, and 400 lM in platelets [19]. Serum
contains factors released from blood cells after the coagulation
process, and plasma does not. Activation of these kinases was fur-
ther examined for 5-HT dose responses in the range 1 nM–10 lM.
5-HT stimulated dose-dependent activation of the seven signaling
kinases (Fig. 1B). This result demonstrated that 5-HT could activate
a set of phosphorylation signaling kinases in human endothelial
cells under physiologically relevant concentrations.
2.2. 5-HT receptor 1B mediates activation of signaling kinases
Studies have shown that the diverse functions of 5-HT are
dependent upon interactions with its speciﬁc receptor subtypes
selectively expressed in different cell types [20,21]. Five 5-HT
receptor subtypes (HTR1A, HTR1B, HTR1D, HTR2B, HTR7) have
been identiﬁed for their expression in human endothelial cells
[9]. Taking advantage of agents and probes developed for selec-
tively targeting each serotonin receptor, speciﬁc antagonists
against the ﬁve 5-HT receptors were applied to assess their role -       +       -       +       -      +        -       +5-HT

















Fig. 1. 5-HT activates signaling kinases in human endothelial cells (A) Human endothe
blotting was conducted with speciﬁc antibodies as indicated to reveal the activation st
human microvascular endothelial cell; HPAEC, human pulmonary artery endothelial cell;
for 5-HT dose–response activation of kinases. HUVECs were stimulated with 5-HT at difin mediating 5-HT signaling. The highly selective HTR1B antagonist
SB216641 [22] blocked the 5-HT-provoked activation of Src, PI3K,
AKT, mTOR, p70S6K, and ERK, whereas the activation of p38 MAPK
was not affected by treatment with SB216641 (Fig. 2A). In contrast
to the HTR1B antagonist that diminished activation of six signaling
kinases, the antagonists against the HTR2B and HTR7 reduced p38
kinase activation but did not affect activation of any other kinases
tested. In addition, the HTR1A antagonist abrogated activation of
p70S6K but did not affect any of the others (Fig. 2A).
The results detailed above suggested that HTR1B might be the
main receptor subtype that mediates 5-HT-activated signaling ki-
nases. Hence, a highly selective HTR1B agonist, CP93129 dihydro-
chloride [23], was applied for further examination. CP93129
could closely resemble the effects of 5-HT on the activation of ki-
nases in human endothelial cells (Fig. 2B). In addition, the HTR1B
antagonist SB216641 could block the 5-HT- and CP93129-stimu-
lated kinase activation of Src, PI3K, AKT, mTOR, p70S6K, and ERK.
Consistently, SB216641 had no effect against the activation of
p38 MAPK stimulated by 5-HT or CP93129. These results provide
further evidence in support of the notion that HTR1B is the main
membrane receptor that mediates the kinase activation induced
by 5-HT.
2.3. GPCRi transduces 5-HT signaling to activate signaling kinases
The 5-HT receptor HTR1B has been characterized as an inhibi-
tory subtype of a G-protein-coupled receptor (GPCRi) [24,25]. Acti-
vation of GPCR leads to its interaction with a G-protein complex
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atus of signaling kinases. (HUVEC, human umbilical vein endothelial cell; HMVEC,
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Fig. 2. 5-HT receptor 1B mediates the activation of signaling kinases (A) HUVEC cultures were treated with selective antagonists at 100 nM as indicated for 1 h followed by 5-
HT stimulation at 100 nM for 15 min. (1A is the HTR1A antagonist WAY100635, 1B is the HTR1B antagonist SB216641, 1D is the HTR1D antagonist BRL15572, 2B is the HTR2B
antagonist SB200646, and 7 is the HTR7 antagonist SB269970). Western blotting of the cell lysates was conducted with the speciﬁc antibodies as indicated. (B) Western
blotting of HUVEC lysates, which were prepared after treatment with 5-HT or a HTR1B agonist (CP93129) at 100 nM for 15 min. In the case of the antagonist, HUVEC cultures
were pre-treated with the HTR1B antagonist SB216641 at 100 nM for 1 h before stimulation with 5-HT or a HTR1B agonist (100 nM) for 15 min.
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transmembrane signal transduction, the activated ai subunit inhib-
its adenylate cyclase (AC) to reduce production of cyclic adenosine
monophosphate (cAMP), and the activated bc subunit catalyzes
the cleavage of phosphatidylinositol bisphosphate (PIP2) to gener-
ate inositol triphosphate (IP3) [26]. cAMP and IP3 are considered to
be important secondary messengers in GPCR signal transduction.
Agonists of 5-HT and HTR1B have shown similar dose-dependent
cAMP down-regulation and IP3 up-regulation in endothelial cells
[9]. The protein-based exotoxin pertussis toxin (PTX) can speciﬁ-
cally ‘‘lock’’ the ai subunit to its inactive state [27]; and the xan-
thene compound gallein selectively binds to the bc subunit
complex with high afﬁnity to block bc-dependent signaling [28].
Using PTX and gallein as biological probes, ai- or bc-dependent ki-
nase activations were examined. By blocking ai or bc, the 5-HT-
evoked activations of AKT, mTOR, and p70S6K were diminished
(Fig. 3A). Activation of p38 MAPK was affected by blocking bc
but not by blocking ai. This observation was consistent with the re-
sult that activation of p38 MAPK was not through GPCRi HTR1B
(Fig. 2A). Activation of PI3K was blocked only by a ai blocker.
2.4. 5-HT stimulates a phosphorylation signaling cascade in
endothelial cells
Several studies have shown that the non-receptor tyrosine ki-
nase Src has important roles in numerous cellular processes, such
as proliferation, survival, and cytoskeleton rearrangement [29].
Stimulation by 5-HT activated Src in endothelial cells through its
receptor subtype HTR1B (Figs. 1 and 2). The ai blocker PTX could
block Src activation, whereas the bc blocker gallein could not, sug-
gesting that Src activation was mediated by ai activation as an up-stream event (Fig. 3A). The Src-selective inhibitor PP2 was then
used to ascertain if other kinase activations were dependent upon
Src activation. Blocking Src activation with PP2 diminished the
activation of PI3K, AKT, mTOR, p70S6K, and ERK (Fig. 3A). This ﬁnd-
ing suggested that activations of these kinases were downstream
of Src activation in 5-HT phosphorylation signaling. Activation of
p38 MAPK was not affected by the blockade of Src activation, sug-
gesting that p38 MAPK was not in the Src downstream signaling
pathway.
To elucidate the sequential signal transduction events of 5-HT
signaling in endothelial cells, the basal effects of selective kinase
inhibitors in endothelial cultures were characterized. Then, opti-
mized concentrations of each inhibitor were obtained for examina-
tion of 5-HT-induced signal transduction. The PI3K-selective
inhibitor LY294002 blocked activation of PI3K, AKT and mTOR
(Fig. 3B). Therefore, PI3K activation was an upstream event of
AKT and mTOR activation. The mTOR inhibitor rapamycin dimin-
ished only the activation of mTOR, and the MEK inhibitor U0126
blocked only ERK activation. Interestingly, neither inhibitors of
PI3K, mTOR, and MEK alone could block 5-HT-activated p70S6K.
This ﬁnding suggested that p70S6K possibly receives multiple in-
puts from different signaling routes evoked by the 5-HT stimulus
in human endothelial cells.
Based on the results described above, a working model of 5-HT
signaling in endothelia is illustrated in Fig. 4. Mediated by GPCR
membrane receptors, 5-HT stimulates more than one intracellular
phosphorylation signaling pathway in human endothelial cells.
One of the pathways is Src/PI3K/AKT/mTOR, which is mediated
by HTR1B. In addition, 5-HT also activated p38 MAPK, ERK, and
p70S6K. These results suggest that the activation of ERK and
p70S6K was mediated by HTR1B, whereas activation of p38 MAPK
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Fig. 3. 5-HT stimulates phosphorylation signaling in endothelial cells (A) HUVEC cultures were treated with the HTR1B antagonist SB216641 at 100 nM (1B), PTX at 1 lg/mL
(Gi), gallein at 10 lM (Gbc), and PP2 at 1 lM (Src) for 1 h followed by 5-HT stimulation at 100 nM for 15 min. Western blotting of the cell lysate was conducted with the
speciﬁc antibodies as indicated. (B) HUVEC cultures were treated with the PI3 K inhibitor LY294002 at 10 lM (PI3 K), mTOR inhibitor (rapamycin) at 10 nM (mTOR), and MEK
inhibitor (U0126) at 100 nM (MEK) for 1 h and followed by 5-HT stimulation at 100 nM for 15 min. Western blotting of the cell lysates was conducted with the speciﬁc
antibodies as indicated.
A. Zamani, Z. Qu / FEBS Letters 586 (2012) 2360–2365 2363may not be through HTR1B. Serine/threonine p70S6K has been re-
ported to be activated by numerous signaling intermediates
(including PI3K and mTOR), and the role of p70S6K and its regula-
tion in 5-HT signaling needs to be investigated further.
2.5. 5-HT and VEGF stimulate the same set of signaling kinases
VEGF is considered to be an important angiogenic factor. VEGF
has been reported to activate several kinases for signal transduc-
tion in endothelia, including the seven kinases examined in the
present study. In the tumor environment, VEGF and 5-HT can
interact with adjacent endothelial cells and activate tumor angio-
genesis. We examined kinase activation in endothelial cells
stimulated by VEGF and 5-HT simultaneously under identical
experimental conditions. In healthy human subjects, the mean lev-
els of VEGF were 42 pg/mL in plasma and 173 pg/mL in serum [30].
However, VEGF above its human serum concentration (200 pg/mL)
could not stimulate kinase activation in endothelial cells (data not
shown). VEGF at a concentration range of 10–25 ng/mL has been
used for the activation of kinases [31]. VEGF and 5-HT could acti-
vate the endothelial signaling kinases Src, PI3K, AKT, mTOR,
p70S6K, ERK, and p38 MAPK, whereas only VEGF could activate
the VEGF receptor VEGFR2 (Fig. 5). The VEGFR2 tyrosine kinase
inhibitor sunitinib could block (or signiﬁcantly reduce) VEGF-pro-
voked kinase activations, whereas it did not have a signiﬁcant ef-
fect on the kinase activation stimulated by 5-HT. Conversely, the
5-HT receptor antagonist SB216641 blocked the 5-HT-provoked ki-
nase activation of Src, PI3K, AKT, mTOR, p70S6K, and ERK, and had
no effect on VEGF-stimulated activation of these signaling kinases.Importantly, the 5-HT concentration in this experiment was
100 nM, which was only one-tenth of the 5-HT concentration in
human serum, and the VEGF concentration was 20 ng/mL, which
was not only much higher than that observed in human serum,
but also much higher than the mean VEGF level of 0.3 ng/mg
protein measured in resected tumor samples from 2800 cancer
patients [30]. This result suggested that, when considering physio-
logically relevant conditions, 5-HT might be a more potent and
relevant angiogenic factor in supporting tumor progression. In
addition, although the action is through different membrane recep-
tors, VEGF and 5-HT activate an identical set of signaling kinases,
demonstrating that the downstream angiogenic signaling path-
ways of VEGF and 5-HT are crossed at several points (or partially
overlapped). Therefore, if blocking one angiogenic factor at its up-
stream signal (e.g., blocking VEGF or VEGFR2), the effect might be
compensated at the downstream signal by the signaling network
stimulated by other angiogenic factors.
3. Discussion
In the recent years, clinical trials focusing on VEGF neutraliza-
tion antibody or inhibitors of the VEGF receptor (VEGFR2) have
shown limited and transient efﬁcacy in cancer treatment [11,14].
This has challenged the current belief of VEGF being a major tumor
angiogenic factor [13,32]. Platelet aggregation and blood coagula-
tion are common features in tumor environments. Platelet activa-
tion leads to a signiﬁcant release of 5-HT in tumor environment.
The released 5-HT can directly interact with adjacent endothelial
cells and lead to activation of angiogenic pathways. Although an
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Fig. 5. 5-HT and VEGF stimulate the same set of signaling kinases. HUVEC lysates
were prepared after treatment with 5-HT at 100 nM or VEGF at 10 ng/mL for
15 min. In the case of antagonists, HUVEC cultures were pre-treated with the HTR1B
antagonist (SB216641) at 100 nM or sunitinib at 100 nM for 1 h and followed by
stimulation with 100 nM 5-HT or 10 ng/mL VEGF for 15 min. Western blotting of
the cell lysates was conducted with the speciﬁc antibodies as indicated.
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known for over hundred years [5,33], however, due to its lack of
a nucleus, the impact of platelets and its stored 5-HT are over-
looked by high-impact, meta-analysis studies focusing on the
genomic proﬁling of tumors. In the present study, we examined
the stimulatory effects of 5-HT on activation of a set of signaling
kinases in human endothelia, and compared them with those seen
with VEGF stimulation. 5-HT at concentrations lower than those
seen in human serum could activate angiogenic signaling kinases,
whereas VEGF at its concentration in human serum (or even at
its concentration in tumors) could not activate the same signal-
ing kinases. These ﬁndings suggested that, when considering
physiologically relevant conditions, 5-HT might be a more potent
angiogenic factor than VEGF in driving tumor angiogenesis. 5-
HT-stimulated angiogenesis may also serve as one of mechanisms
underlying the resistance of current VEGF-targeting anti-angio-
genic therapy in cancer.
4. Materials and methods
4.1. Cell cultures, inhibitors and chemical agents
HUVECs, HPAECs, HMVECs, and HAECs (Lonza, Walkersville,
MD, USA) were maintained in culture with a full growth medium
as Endothelial Basal Medium (EBM) (Lonza) supplemented with
2% fetal bovine serum (FBS), 0.4% bovine brain extract (Lonza)
and 1/1000 GA-1000 (gentamicin, amphotericin-B). Serotonin cre-
atinine sulfate monohydrate (5-HT) was obtained from Sigma–Al-
drich (St. Louis, MO, USA). CP93129 dihydrochloride, WAY100635maleate, SB216641 hydrochloride, BRL15572 hydrochloride,
SB206553 hydrochloride, SB269970 hydrochloride, PTX, gallein,
PP2, LY294002, U0126 and rapamycin were obtained from Tocris
Biosciences (Ellisville, MO, USA). SU11248 (sunitinib) was obtained
from Pﬁzer (New York, NY, USA). Recombinant human VEGF (165
amino acids) was from R&D Systems (Minneapolis, MN, USA).
4.2. Endothelial stimulation experiments and western blotting
analyses
For all endothelial stimulation experiments, cell cultures were
ﬁrst switched to Basic Medium (EBM plus 0.1% FBS) for 1-h starva-
tion, and different treatments were then undertaken. Only primary
endothelial cultures between passages 3 and 5 (conﬂuence, 90%)
were used for 5-HT stimulation experiments. Endothelial cell ly-
sates were prepared with cell lysis buffer (10 mM Tris–HCl buffer
at pH 8, 100 mM sodium phosphate, 3 M urea, 1% sodium dodecyl
sulfate (SDS) and 5% 2-mercaptoethanol). Cell lysates under differ-
ent treatment conditions were subjected to 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Western
blots were conducted with speciﬁc primary and secondary anti-
bodies, and visualized with high-sensitivity enhanced chemilumi-
nescence (ECL) (Amersham-Pharmacia, Uppsala, Sweden). All
primary antibodies were obtained from Cell Signaling (Danvers,
MA, USA) as speciﬁc antibodies against the kinase proteins of
VEGFR2, Src, PI3K, AKT, ERK, mTOR, p70S6K, and p38 MAPK; and
antibodies against the phospho-speciﬁc sites of these kinases as
anti-phospho-VEGFR2 (Tyr 951), phospho-Src (Tyr 416), phos-
pho-PI3K (Tyr 458/199), phospho-AKT (Thr 308), phospho-ERK
(Thr 202/Tyr 204), phospho-mTOR (Ser 2448), phospho-p70S6K
(Thr 421/Ser 424), and phospho-p38 (Thr180/Tyr182). Each of
A. Zamani, Z. Qu / FEBS Letters 586 (2012) 2360–2365 2365the western blotting experiments were conducted at least two
times to conﬁrm the study results.
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